Alnylam Pharmaceuticals said today it has earned a $20 million milestone payment from Japan-based Takeda Pharmaceutical as part of the collaboration formed between the companies in May. The money is for transferring documents, materials, and know-how to Takeda for developing RNA interference-based drugs. Alnylam (NASDAQ: [[ticker:ALNY]]) has already received a $100 million upfront payment from Takeda for closing the deal.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
